Table 1. Group statistics of the GWAS and the replication study cohorts.

	GWAS validation						Replication study
	Enrolled			After TaqMan® filtration			Enrolled			After TaqMan® filtration
	N	Range	Median	N	Range	Median	N	Range	Median	N	Range	Median
PCa	135	45–83	67	118	45–83	58	447	42–83	67	419	42–83	67
AD	525	27–85	59	476	27–85	59	945	32–85	60	856	36–85	60
AD (F)	270	28–85	58	242	28–85	58	509	32–85	60	454	40–85	60
AD (M)	255	27–85	60	234	27–85	60	436	36–85	61	402	36–85	61
CRC	630	29–86	65	598	29–86	65	889	28–89	64	840	29–89	64
CRC (F)	240	29–86	63	234	29–86	63	352	29–89	63	341	29–89	63
CRC (M)	390	32–84	66	364	32–84	66	537	28–85	65	499	30–85	65
Control - PCa	270	27–81	55	261	27–81	55	800	27–86	59	772	27–86	59
Control - AD/CRC	690	27–81	57	669	27–81	57	2188	21–87	58	1981	21–87	58
Control - AD/CRC (F)	420	40–77	58	408	40–77	58	1542	21–87	58	1399	21–87	58
Control - AD/CRC (M)	270	27–81	55	261	27–81	55	646	24–82	57.5	582	24–82	57

The GWAS validation panel indicates numbers of patients (N) enrolled in the GWAS, after excluding microarrays that did not meet quality control criteria based on the PCA results. The ‘Range’ and ‘Median’ values regard age of cases and controls in respective groups. Both GWAS validation and replication analyses were done using respective individual patient TaqMan® genotyping. The TaqMan® genotyping data was subjected to a quality filtration using the 5% threshold of per-individual maximum genotype missingness (see ‘Statistical analyses – individual genotyping’).